echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Serum phosphate, a neglected indicator in the clinical treatment of primary hyperparathyroidism

    JCEM: Serum phosphate, a neglected indicator in the clinical treatment of primary hyperparathyroidism

    • Last Update: 2021-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Typical primary hyperparathyroidism (PHPT) is characterized by high parathyroid hormone concentration, high serum and urine calcium content, low serum phosphate (P) concentration, and detection of serum calcium (Ca) level for the diagnosis of PHPT It is very important and is included in the standard of asymptomatic PHPT (aPHPT) surgical treatment recommended by the latest international guidelines together with 24-hour urine calcium (UCa)
    .


    Serum and urine P levels have nothing to do with the diagnosis of PHPT, nor are they included in the criteria for surgery in PHPT patients


     Typical primary hyperparathyroidism (PHPT) is characterized by high parathyroid hormone concentration, high serum and urine calcium content, low serum phosphate (P) concentration, and detection of serum calcium (Ca) level for the diagnosis of PHPT It is very important and is included in the standard of asymptomatic PHPT (aPHPT) surgical treatment recommended by the latest international guidelines together with 24-hour urinary calcium (UCa)


    The two-site immunochemiluminescence assay (Immulite 2000; DPC, Los Angeles, CA) was used to measure the serum intact PTH concentration until 2012, and the inter-assay and intra-assay coefficients of variation were 6.
    3% to 8.
    8% and 4.
    2% to 5.
    7%, respectively
    .


    After 2012, the new second-generation immunochemiluminescence assay (Cobas e411, Roche Diagnostics) was used to measure the serum intact PTH concentration, and the inter-assay and intra-assay coefficients of variation were 3.


    The radioimmunoassay (DIAsource 25OHVit) was used to determine the serum 25-hydroxyvitamin D (25OHD) level
    .


    D3-Ria-CT kit-DIAsource immunoassay (Nivelles, Belgium), the detection limit is 0.


    Throughout the study, the same instrument (DXA QDR-4500, Holoch, Bedford, Massachusetts) was used to measure the bone mineral density of the lumbar spine (L2-L4), proximal femur, and distal radius of the non-dominant
    .


    The slight upgrade of the bone densitometer, especially in terms of reporting and process duration, did not significantly affect the results


    All patients underwent a standard renal ultrasound examination, using a 2-5 MHz broadband convex transducer
    .


    In order to confirm the diagnosis of stones, so that patients can be classified as positive or negative for kidney stones, radiologists look for hyperechoic spots with a diameter of more than 2 mm and perform multi-planar evaluation of specific signs, such as echo, posterior acoustic shadow, or positive Flickering signs


    Results: 198/472 patients had P levels lower than 2.
    5 mg/dL (HypoP), accounting for 41.
    9%
    .


    Mild (2-2.


    The P level of men is lower than that of women .


    Table 1 Comparison of P levels (mg/dL) in 472 PHPT patients based on demographic and clinical characteristics

    Table 1 Comparison of P levels (mg/dL) in 472 PHPT patients based on demographic and clinical characteristics

    Table 2 Comparison of P levels (mg/dL) among PHPT patients subdivided according to demographic and clinical characteristics

    Table 2 Comparison of P levels (mg/dL) among PHPT patients subdivided according to demographic and clinical characteristics

    Table 3 Comparison of PHPT patients with and without hypophosphatemia

    Table 3 Comparison of PHPT patients with and without hypophosphatemia

    Table 4 Single-factor correlation analysis of blood phosphorus levels and demographic and clinical parameters in PHPT patients

    Table 4 Single-factor correlation analysis of blood phosphorus levels and demographic and clinical parameters in PHPT patients

    Conclusion: We observed the relationship between P level and the biochemical and clinical characteristics of PHPT severity
    .


    In asymptomatic PHPT patients, even moderate HypoP can predict surgical indications regardless of age and severity of hypercalcemia


    We observed a relationship between P levels and the biochemical and clinical characteristics of PHPT severity
    .
    In asymptomatic PHPT patients, even moderate HypoP can predict surgical indications regardless of age and severity of hypercalcemia
    .

    Original source:

    Castellano E, Attanasio R, Boriano A, Pellegrino M, Borretta G, Serum Phosphate: A Neglected Test In The Clinical Management Of Primary Hyperparathyroidism .
    J Clin Endocrinol Metab 2021 Sep 14

    Serum Phosphate: A Neglected Test In The Clinical Management Of Primary Hyperparathyroidism in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.